Little is known about the risk of hepatitis B virus (HBV) reactivation in patients receiving interferon (IFN)-free direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV).
Hepatitis C virus (HCV) infection is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation [1] [2] [3] . Compared with HCV-infected patients who fail to achieve sustained virologic response (SVR) after antiviral therapies, those who achieve SVR have decreased long-term morbidity and mortality [4, 5] . Treatment of HCV by interferon (IFN)-free direct-acting antiviral agents (DAAs) has shown excellent efficacy and safety. Applying IFN-free DAAs has become the current standard of care for the management of HCV infection.
Although treatment with IFN-free DAAs is generally considered to be potent and safe, several case reports have shown that HCV-infected patients who were seropositive for hepatitis B virus (HBV) surface antigen (HBsAg) or isolated HBV core antibody (anti-HBc) developed HBV reactivation after IFNfree DAAs with the presentation of increasing serum HBV viral load, alanine aminotransferase (ALT) elevation, or even hepatic decompensation [6] [7] [8] [9] . Based on the case reports, the US Food and Drug Administration and the American Association for the Study of Liver Diseases/Infectious Diseases Society of America posted warning information of potential HBV reactivation for HCV-infected patients receiving IFN-free DAAs [10, 11] . Recently, one study evaluated the risk of HBV reactivation in HCV-infected patients receiving IFN-free DAAs and concluded that HBsAg-positive patients had a higher risk of HBV reactivation than HBsAg-negative patients (30% vs 0%) [12] . However, the incidence and the clinical features of HBV reactivation after IFN-free DAAs for HCV have not been fully addressed by prospective studies. Therefore, we aimed to prospectively evaluate the risk of HBV reactivation in patients receiving IFN-free DAAs for HCV.
at the National Taiwan University Hospital (NTUH) and NTUH Yun-Lin Branch. All patients were aged ≥20 years and had chronic HCV infection, defined as detectable HCV antibody ([anti-HCV] Abbott HCV EIA 3.0; Abbott Laboratories, Abbott Park, IL) and serum HCV ribonucleic acid (RNA) (Cobas TaqMan HCV Test version 2.0; Roche Diagnostics GmbH, Mannheim, Germany; limit of quantification, 25 IU/ mL) for more than 6 months. In addition, all patients received treatment for 12 weeks and off-therapy follow-up for an additional 12 weeks according to label recommendations. The study was approved by the NTUH Institutional Review Board and was conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. All patients provided written informed consent before participating in the study.
Study Design
This was a prospective cohort study. Baseline demographic data, hemogram, international normalized ratio (INR), serum albumin, serum bilirubin, serum ALT, stage of hepatic fibrosis, anti-HCV, HBsAg (Abbott Architect HBsAg quantification assay; Abbott Laboratories), HBV surface antibody (anti-HBs) (Abbott Architect anti-HBs assay; Abbott Laboratories), antiHBc (Abbott Architect anti-HBc II assay; Abbott Laboratories), HCV RNA, HCV genotype (Abbott RealTime HCV genotyping II; Abbott Molecular Inc., Chicago, IL), and HBV deoxyribonucleic acid ([DNA] Cobas AmpliPrep/Cobas TaqMan HBV DNA test, version 2.0; limit of detection 12 IU/mL and limit of quantification 20 IU/mL) were assessed before IFN-free DAA treatment [13, 14] . Patients who were seronegative for anti-HBc and who did not complete 12 weeks of IFN-free DAAs were excluded. In addition, Patients were excluded from the study if they received peginterferon or oral nucleos(t)ide analogues that were active against HBV within 24 weeks before the start of IFN-free DAAs.
After IFN-free DAAs, all patients received outpatient visits at weeks 1, 2, 4, 6, 8, and then every 4 weeks until the last visit. The hemogram, INR, albumin, bilirubin, ALT, HBsAg, HBV DNA, and HCV RNA were evaluated at each visit. Hepatitis B virus reactivation was defined as reappearance of serum HBV DNA ≥100 IU/mL in patients with baseline undetectable viral load or ≥2 log 10 IU/mL increase of HBV DNA in patients with baseline detectable viral load [15, 16] . Furthermore, we evaluated low-level HBV rebound, defined as reappearance of detectable HBV DNA in patients with baseline undetectable viral load or in those with ≥1 log 10 IU/mL increase from baseline detectable viral load. Hepatitis B virus-related ALT flare was defined as ALT ≥5 times upper limit of normal or ≥2 times of the baseline level with concomitant HBV DNA reactivation [15] . Hepatitis B virus-related hepatic decompensation was defined as presence of HBV-related ALT flare and presence of jaundice, coagulopathy, hepatic encephalopathy, or ascites. Patients would receive oral entecavir or tenofovir disoproxil fumarate therapy if they developed HBV-related ALT flare and/or hepatic decompensation during the study. Hepatitis B virus surface antigen seroreversion was defined as reappearance of HBsAg after IFN-free DAA treatment in HBsAg-negative patients.
The risk of HBV reactivation, HBV-related ALT flare, and HBV-related hepatic decompensation were evaluated for all patients who completed 12 weeks of IFN-free DAAs. For patients who had completed off-therapy follow-up for 12 weeks, the risk of off-therapy HBV reactivation and the related clinical events were also evaluated.
Statistical Analyses
Data were analyzed using Statistical Program for Social Sciences (SPSS 17.0; SPSS Inc., Chicago, IL). Patient characteristics were expressed as mean (standard deviation) and percentage when appropriate. The events related to HBV reactivation, ALT flare, hepatic decompensation, and HBsAg seroreversion were shown in numbers and percentages with 95% confidence interval (CI) and were compared by χ 2 with Fisher's exact test when appropriate. All statistical tests were 2-tailed, and the results were statistically significant when a P value was <.05.
RESULTS

Patient Characteristics
Among the 134 enrolled patients, 26 seronegative for antiHBc were excluded. Of the 108 patients seropositive for antiHBc, 13 who did not complete 12 weeks of treatment and 2 human immunodeficiency virus (HIV)-infected patients who were seronegative for HBsAg but who receive received nucleos(t)ide reverse-transcriptase inhibitors active against HBV were excluded. Among the 13 patients who did not complete treatment, 1 HBsAg-negative patient developed hepatic decompensation 1 week after paritaprevir/ritonavir, ombitasvir plus dasabuvir (PrOD)-based treatment. The baseline and week-1 HBV DNA levels were undetectable, indicating that this event was not attributed to HBV reactivation. The remaining 12 HBsAg-positive and 81 HBsAgnegative patients were eligible for the study. Furthermore, 86 patients completed off-therapy follow up for 12 weeks ( Figure 1 With regard to HBsAg dynamics, the HBsAg levels decreased during DAA therapies and rebounded after stopping treatment in all patients. Furthermore, the changes of HBsAg levels were not correlated to the HBV dynamics. The baseline HBsAg levels of the 2 patients with HBV reactivation were 844.5 and 585.74 IU/mL, respectively. The HBsAg levels were less than 500 IU/ mL in the remaining 10 patients without HBV reactivation. 
DISCUSSION
Our study demonstrated the following findings: (1) no HBV reactivation was observed in HBsAg-negative patients receiving IFN-free DAAs for HCV [12, 17] ; (2) the HBV reactivation was limited to HBsAg-positive patients, but there were no HBV-related ALT flare and/or hepatic decompensation; (3) there was no additional risk of HBV reactivation after stopping DAA treatment for HCV, which was frequently observed in HBsAg-positive patients receiving immunosuppressive agents [15, 16] . [14] . Two HBsAg-negative patients and 1 HBsAgpositive patient had unreliable examination with less than 10 valid measurements, a successful rate of less than 60%, and the IQR more than 30% of the median liver stiffness measurement value.
In recent studies, several case reports indicated that patients who were seropositive for HBsAg or isolated anti-HBc experienced HBV reactivation and its clinical events after IFN-free DAAs for HCV, raising the concerns for HBV monitoring and prophylactic use of oral anti-HBV agents [6] [7] [8] [9] . Our study was in line with the Wang et al [12] report that the risk of HBV reactivation was significantly higher in HBsAg-positive patients compared with HBsAg-negative patients. Although the risk of HBV reactivation in HBV-positive patients was comparable between our (16.7% [95% CI, 4.7%-44.8%]) and the Wang et al [12] studies (30.0% [95% CI, 10.8%-60.3%]), we did not observe any HBV-related ALT flare or hepatic decompensation. Furthermore, there was no ALT elevation before or at the peak of HBV DNA levels in HBsAg-positive patients with HBV reactivation, indicating that on-treatment ALT monitoring may not be sensitive enough to detect HBV reactivation.
With regard to HBsAg-negative patients, our study was also in line with the Wang et al [12] report that none developed HBV reactivation after IFN-fee DAAs for HCV. In addition, none of our HBsAg-negative patients developed HBsAg seroreversion, which was frequently observed in those receiving anti-CD20 or hematopoietic stem cell transplantation [15] . Although 1 case report describing a patient with isolated anti-HBc seropositivity developed HBV reactivation and hepatic decompensation after IFN-free DAAs, the presence of anti-HBc immunoglobulin M and HBsAg may indicate HBV superinfection rather than HBV reactivation [9, 18] .
Although the HBV DNA dynamics in our HBsAg-positive patients were poorly correlated to the HBsAg dynamics, the HBsAg levels decreased during IFN-free DAAs and rebounded after stopping treatment. The baseline HBsAg levels of 2 patients with HBV reactivation were numerically higher than those of the remaining 10 patients without HBV reactivation. The clinical relevance of HBsAg dynamics to HBV reactivation in HBsAg-positive patients receiving IFN-free DAAs are still unclear. Further studies are needed to explore the potential mechanisms.
Our study had 2 limitations. First, the number for HBsAgpositive patients was small, and more patients should be evaluated to confirm the dynamic changes of serum HBV DNA/ HBsAg levels and the clinical events in these patients. Second, our HBsAg-positive patients were all inactive HBV carriers (HBV DNA level <2000 IU/mL). The risk of HBV reactivation and the clinical events in active HBV carriers await more studies. 
CONCLUSIONS
In conclusion, HBsAg-negative patients receiving IFN-free DAAs for HCV have a low risk of HBV reactivation. In contrast, HBsAg-positive patients receiving IFN-free DAAs for HCV have a significantly higher risk of HBV reactivation, although the risk of HBV-related ALT flare or hepatic decompensation is low. Whether baseline HBsAg levels can predict HBV reactivation after IFN-free DAAs need further confirmation.
